These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25642445)

  • 1. The Effect of Osteoporosis Treatments on Fatigue Properties of Cortical Bone Tissue.
    Brock GR; Chen JT; Ingraffea AR; MacLeay J; Pluhar GE; Boskey AL; van der Meulen MC
    Bone Rep; 2015 Jun; 2():8-13. PubMed ID: 25642445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of osteoporosis medications on bone quality.
    Benhamou CL
    Joint Bone Spine; 2007 Jan; 74(1):39-47. PubMed ID: 17196423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel non-steroidal selective androgen receptor modulator S-101479 has additive effects with bisphosphonate, selective estrogen receptor modulator, and parathyroid hormone on the bones of osteoporotic female rats.
    Furuya K; Yamamoto N; Ohyabu Y; Makino A; Morikyu T; Ishige H; Kuzutani K; Endo Y
    Biol Pharm Bull; 2012; 35(7):1096-104. PubMed ID: 22791158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alendronate treatment alters bone tissues at multiple structural levels in healthy canine cortical bone.
    Acevedo C; Bale H; Gludovatz B; Wat A; Tang SY; Wang M; Busse B; Zimmermann EA; Schaible E; Allen MR; Burr DB; Ritchie RO
    Bone; 2015 Dec; 81():352-363. PubMed ID: 26253333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent Parathyroid Hormone After Prolonged Alendronate Treatment Induces Substantial New Bone Formation and Increases Bone Tissue Heterogeneity in Ovariectomized Rats.
    Altman-Singles AR; Jeong Y; Tseng WJ; de Bakker CM; Zhao H; Lott C; Robberts J; Qin L; Han L; Kim DG; Liu XS
    J Bone Miner Res; 2017 Aug; 32(8):1703-1715. PubMed ID: 28467646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication management after intramedullary nailing of atypical fractures.
    Feron JM; Cambon-Binder A
    Injury; 2017 Jun; 48 Suppl 1():S15-S17. PubMed ID: 28456365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats.
    Ma YL; Bryant HU; Zeng Q; Schmidt A; Hoover J; Cole HW; Yao W; Jee WS; Sato M
    Endocrinology; 2003 May; 144(5):2008-15. PubMed ID: 12697709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.
    Gallacher SJ; Dixon T
    Calcif Tissue Int; 2010 Dec; 87(6):469-84. PubMed ID: 20872215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of raloxifene and alendronate on non-enzymatic collagen cross-links and bone strength in ovariectomized rabbits in sequential treatments after daily human parathyroid hormone (1-34) administration.
    Kimura S; Saito M; Kida Y; Seki A; Isaka Y; Marumo K
    Osteoporos Int; 2017 Mar; 28(3):1109-1119. PubMed ID: 27796444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged treatments with antiresorptive agents and PTH have different effects on bone strength and the degree of mineralization in old estrogen-deficient osteoporotic rats.
    Cheng Z; Yao W; Zimmermann EA; Busse C; Ritchie RO; Lane NE
    J Bone Miner Res; 2009 Feb; 24(2):209-20. PubMed ID: 18847326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new contralateral atypical femoral fracture despite sequential therapy with teriparatide and strontium ranelate.
    Nguyen HH; Milat F; Ebeling PR
    Bone Rep; 2017 Jun; 6():34-37. PubMed ID: 28377979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical femur fracture in an adolescent boy treated with bisphosphonates for X-linked osteoporosis based on PLS3 mutation.
    van de Laarschot DM; Zillikens MC
    Bone; 2016 Oct; 91():148-51. PubMed ID: 27477003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical femoral fractures and current management.
    Zheng N; Tang N; Qin L
    J Orthop Translat; 2016 Oct; 7():7-22. PubMed ID: 30035084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The teriparatide in the treatment of severe senile osteoporosis.
    Manuele S; Sorbello L; Puglisi N; Grasso S; La Malfa L; D'Urbino G; Rizzotto M; Strano S; Maugeri D
    Arch Gerontol Geriatr; 2007; 44 Suppl 1():249-58. PubMed ID: 17317460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Risk Factors for Atypical Femoral Fractures (AFFs): A Systematic Review.
    Nguyen HH; van de Laarschot DM; Verkerk AJMH; Milat F; Zillikens MC; Ebeling PR
    JBMR Plus; 2018 Jan; 2(1):1-11. PubMed ID: 30283886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dramatic increase in cortical thickness induced by femoral marrow ablation followed by a 3-month treatment with PTH in rats.
    Zhang Q; Carlson J; Ke HZ; Li J; Kim M; Murphy K; Mehta N; Gilligan J; Vignery A
    J Bone Miner Res; 2010 Jun; 25(6):1350-9. PubMed ID: 20200940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of osteoporosis due to ovarian failure.
    Eastell R
    Med Pediatr Oncol; 2003 Sep; 41(3):222-7. PubMed ID: 12868123
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.